Mutation distribution in the von Willebrand factor gene related to the different von Willebrand disease (VWD) types in a cohort of VWD patients

Summary

Von Willebrand disease (VWD) is the most common inherited bleeding disorder caused by quantitative or qualitative defects of the von Willebrand factor (VWF). VWD is classified into three types – type 1 (partial quantitative deficiencies), type 2 (qualitative defects) and type 3 (complete deficiency of VWF). In this study we explored genotype and phenotype characteristics of patients with VWD with the aim of dissecting the distribution of mutations in different types of VWD. One hundred fourteen patients belonging to 78 families diagnosed to have VWD were studied. Mutation analysis was performed by direct sequencing of the VWF. Large deletions were investigated by multiplex ligation-dependent probe amplification (MLPA) analysis. The impact of novel candidate missense mutations and potential splice site mutations was predicted by in silico assessments. We identified mutations in 66 index patients (IPs) (84.6%). Mutation detection rate was 68%, 94% and 94% for VWD type 1, 2 and 3, respectively. In total, 68 different putative mutations were detected comprising 37 missense mutations (54.4%), 10 small deletions (14.7%), two small insertions (2.9%), seven nonsense mutations (10.3%), five splice-site mutations (7.4%), six large deletions (8.8%) and one silent mutation (1.5%). Twenty-six of these mutations were novel. Furthermore, in type 1 and type 2 VWD, the majority of identified mutations (74% vs. 88.1%) were missense substitutions while mutations in type 3 VWD mostly caused null alleles (82%). Genotyping in VWD is a helpful tool to further elucidate the pathogenesis of VWD and to establish the relationship between genotype and phenotype.

Keywords

VWF mutations - von Willebrand disease - VWD phenotype - VWD types - VWF A1 domain

• References

• 1 Goodeve AC. The genetic basis of von Willebrand disease. Blood Rev 2010; 24: 123-134.
• 2 Keeney S, Bowen D, Cumming A. et al. The molecular analysis of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organisation Haemophilia Genetics Laboratory Network. Haemophilia 2008; 14: 1099-1111.
• 3 Mancuso DJ, Tuley EA, Westfield LA. et al. Structure of the gene for human von Willebrand factor. J Biol Chem 1989; 264: 19514-19527.
• 4 Castaman G, Federici AB, Rodeghiero F. et al. Von Willebrand’s disease in the year 2003: towards the complete identification of gene defects for correct diagnosis and treatment. Haematologica 2003; 88: 94-108.
• 5 Sadler JE, Budde U, Eikenboom JC. et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Wille-brand Factor. J Thromb Haemost 2006; 04: 2103-2114.
• 6 Federici AB. Classification of inherited von Willebrand disease and implications in clinical practice. Thromb Res 2009; 124: S2-S6.
• 7 Peake I, Goodeve A. Type 1 von Willebrand disease. J Thromb Haemost 2007; 05: 7-11.
• 8 Lillicrap D. Genotype/phenotype association in von Willebrand disease: is the glass half full or empty?. J Thromb Haemost 2009; 07: 65-70.
• 9 Schneppenheim R, Budde U, Obser T. et al. Expression and characterization of von Willebrand factor dimerization defects in different types of von Willebrand disease. Blood 2001; 97: 2059-2066.
• 10 Budde U. Diagnosis of von Willebrand disease subtypes: implications for treatment. Haemophilia 2008; 14: 27-38.
• 11 Schneppenheim R, Lenk H, Obser T. et al. Recombinant expression of mutations causing von Willebrand disease type Normandy: characterization of a combined defect of factor VIII binding and multimerization. Thromb Haemost 2004; 92: 36-41.
• 12 Schneppenheim R. The pathophysiology of von Willebrand disease: therapeutic implications. Thromb Res 2011; 128: S3-S7.
• 13 Collins PW, Cumming AM, Goodive AC. et al. Type 1 von willebrand disease: application of emerging data to clinical practice. Haemophilia 2008; 14: 685-696.
• 14 Goodive A, Eikenboom J, Castaman G. et al. Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD). Blood 2007; 109: 112-121.
• 15 James PD, Notley C, Hegadorn C. et al. The mutational spectrum of type 1 von Willebrand disease: results from a Canadian cohort study. Blood 2007; 109: 145-154.
• 16 Cumming A, Grundy P, Keeney S. et al. An investigation of the von Willebrand factor genotype in UK patients diagnosed to have type 1 von Willebrand disease. Thromb Haemost 2006; 96: 630-641.
• 17 Budde U, Schneppenheim R, Eikenboom J. et al. Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD). J Thromb Haemost 2008; 06: 762-771.
• 18 Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215.
• 19 Ng PC, Henikoff S. SIFT: Predicting amino acid changes that affect protein function. Nucleic Acids Res 2003; 31: 3812-3814.
• 20 Yadegari H, Driesen J, Hass M. et al. Large deletions identified in patients with von Willebrand disease using multiple ligation-dependent probe amplification. J Thromb Haemost 2011; 09: 1083-1086.
• 21 Huizinga EG, Tsuji S, Romijn RA. et al. Structures of glycoprotein Ib alpha and its complex with von Willebrand factor A1 domain. Science 2002; 297: 1176-1179.
• 22 Emsley J, Cruz M, Handin R. et al. Crystal structure of the von Willebrand Factor A1 domain and implications for the binding of platelet glycoprotein Ib. J Biol Chem 1998; 273: 10396-10401.
• 23 Pettersen EF, Goddard TD, Huang CC. et al. UCSF Chimera-visualization system for exploratory research and analysis. J Comput Chem 2004; 25: 1605-12. http://www.cgl.ucsf.edu/chimera/ Accessed November 6, 2006.
• 24 Mills JEJ, Dean PM. Three-dimensional hydrogen-bond geometry and probability information from a crystal survey. J Comput-Aided Mol Des 1996; 10: 607.
• 25 James PD, Paterson AD, Notley C. et al. Genetic linkage and association analysis in type 1 von Willebrand disease: results from the Canadian Type 1 VWD Study. J Thromb Haemost 2006; 04: 783-792.
• 26 Eikenboom J, Van Marion V, Putter H. et al. Linkage analysis in families diagnosed with type 1 von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 VWD. J Thromb Haemost 2006; 04: 774-782.
• 27 Hermans C, Batlle J. Autosomal dominant von Willebrand disease type 2M. Acta Haematol 2009; 121: 139-144.
• 28 Corrales I, Catarino S, Ayats J. et al. High-throughput molecular diagnosis of von Willebrand disease by next generation sequencing methods. Haematologica. 2012 Epub ahead of print.
• 29 Robertson JD, Yenson PR, Rand ML. et al. Expanded phenotype correlations in a pediatric population with type 1 von Willebrand disease. J Thromb Haemost 2011; 09: 1752-1760.
• 30 Sutherland MS, Keeney S, Bolton-Maggs PHB. et al. The mutation spectrum associated with type 3 von Willebrand disease in a cohort of patients from the North West of England. Haemophilia 2009; 15: 1048-1057.
• 31 Baronciani L, Cozzi G, Canciani MT. et. al. Molecular defects in type 3 von Wille-brand disease: updated results from 40 multiethnic patients. Blood Cell Mol Dis 2003; 30: 264-270.
• 32 Baronciani L, Cozzi G, Canciani MT. et. al. Molecular characterization of a multiethnic group of 21 patients with type 3 von Willebrand disease. Thromb Haemost 2000; 84: 536-540.
• 33 Gadisseur A, van der Planken M, Schroyens W. et al. Dominant von Willebrand disease type 2M and 2U are variable expressions of one distinct disease entity caused by loss-of-function mutations in the A1 domain of the von Willebrand factor gene. Acta Haematol 2009; 121: 145-153.
• 34 Corrales I, Ramirez L, Altisent C. et al. Rapid molecular diagnosis of von Wille-brand disease by direct sequencing. Detection of 12 novel putative mutations in VWF gene. Thromb Haemost 2009; 101: 570-576.
• 35 James PD, Notley C, Hegadorn C. et al. Challenges in defining type 2M von Wille-brand disease: results from a Canadian cohort study. J Thromb Haemost 2007; 05: 1914-1922.
• 36 Berber E, James PD, Hough C. et al. An assessment of the pathologenic significance of the R924Q von Willebrand factor substitution. J Thromb Haemost 2009; 07: 1672-1679.
• 37 Hickson N, Hampshire D, Winship P. et al. bon behalf of the MCMDM-1VWD and ZPMCB-VWD Study Groups. von Willebrand factor variant p.Arg924Gln marks an allele associated with reduced von Willebrand factor and factor VIII levels. J Thromb Haemost 2010; 08: 1986-1993.
• 38 Eikenboom J, Hilbert L, Ribba AS. et al. Expression of 14 von Willebrand factor mutations identified in patients with type 1 von Willebrand disease from the MCMDM-1VWD study. J Thromb Haemost 2009; 07: 1304-1312.
• 39 Allen S, Abuzenadah AM, Blagg JL. et al. Two novel type 2N von Willebrand disease-causing mutations that result in defective factor VIII binding, multimerization, and secretion of von Willebrand factor. Blood 2000; 95: 2000-2007.
• 40 McKinnon TA, Goode EC, Birdsey GM. et al. Specific N-linked glycosylation sites modulate synthesis and secretion of von Willebrand factor. Blood 2010; 116: 640-648.
• 41 Corrales I, Ramirez L, Altisent C. et al. The study of the effect of splicing mutations in von Willebrand factor using RNA isolated from patients’ platelets and leukocytes. J Thromb Haemost 2011; 09: 679-688.
• 42 Zhang Q, Zhou YF, Zhang CZ. et al. Structural specializations of A2, a force-sensing domain in the ultralarge vascular protein von Willebrand factor. Proc Natl Acad Sci USA 2009; 106: 9226-9231.